CAS 845816-02-6|Lexatumumab
Introduction：Basic information about CAS 845816-02-6|Lexatumumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lexatumumab | ||
|---|---|---|---|
| CAS Number | 845816-02-6 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Lexatumumab |
|---|
Lexatumumab BiologicalActivity
| Description | Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces Apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>Apoptosis >>ApoptosisResearch Areas >>Cancer |
| Target | TRAIL-R2[1] |
| In Vitro | The combination of Cisplatin (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death[1]. Lexatumumab (0-10 µg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines[2]. Cell Viability Assay[2] Cell Line: Melanoma cell lines Concentration: 0.01, 0.1, 1.0 and 10.0 µg/ml Incubation Time: 72 h Result: Induced various degrees of cell death in the different cell lines. |
| In Vivo | Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with Dacarbazine (HY-B0078)[2]. Animal Model: FEMX-1 xenografts mice[2] Dosage: 10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection) Administration: i.v., twice a week Result: Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis. |
| References | [1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66. [2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
